Research

How to Choose a Tirzepatide Provider: 7 Checks

Creator: Elena Marsh, Health Writer
Published: 2026-09-10

Most of the difference between a careful service and a careless one shows up before a vial ever arrives — in who reads your history, who makes the medicine, and whether anyone answers afterwards.

Elena Marsh, Health Writer September 10, 2026 7 min read

A woman sits in a linen armchair beside a bright window, holding a plain ceramic mug in both hands

The short version

Four checks decide most of it: the clinician is licensed in the state where you sit for the visit, the intake covers your medical history, the pharmacy that compounds the medicine is named, and a clinician can decline you.
On June 8, 2026 the FDA issued warning letters, posted June 16, to at least fifteen telehealth companies selling compounded semaglutide and tirzepatide.
FDA told those companies that compounding facilities are not “FDA-approved” or “FDA-licensed” entities — there is no such status, so a site claiming it is telling you nothing true.
A 2026 analysis of 81,078 GLP-1 adverse-event reports found 707 involving compounded products, with higher reported odds of preparation and prescribing errors and roughly double the odds of a mentioned hospitalization.
The approved tirzepatide label rules the medicine out for a personal or family history of medullary thyroid carcinoma or MEN 2 — if your intake never asked, it was not a clinical review.
FDA's consumer guidance, current as of September 1, 2026, says to buy only from state-licensed pharmacies and to be wary of services that do not require a licensed doctor's prescription.

Here's how to choose a tirzepatide provider: look for four things before you look at anything else. A clinician licensed in the state where you'll be sitting during the visit. A medical history form that asks about your health, not just your goal weight. A named pharmacy that actually makes the medicine. And a way to reach a person after the first box arrives.

That sounds obvious. It isn't — because the services that fail those tests look almost identical to the ones that pass. Same clean photography, same three-step graphic, same monthly price. The difference shows up after you hit submit, where you can't see it.

So here is what to look at instead.

How to choose a tirzepatide provider: the seven checks

1. The clinician is licensed where you are. Not where the company has its office — where you are physically sitting during the visit. That's the state whose rules govern the encounter, which is why a legitimate service asks your state early rather than at checkout. If you want to verify the person yourself, we walk through it in how to check if a telehealth doctor is licensed.

2. The intake asks about your health. Height, weight and a card number is a purchase, not a medical review. A real intake asks what medications you take, what you've been diagnosed with, and what runs in your family.

3. Someone can tell you no. This is the one people find counterintuitive. A service where every applicant gets a prescription has a clinician in name only. Being declined is the system working — and it's usually specific and fixable.

4. You're told who makes it. Compounded tirzepatide is prepared by a licensed pharmacy. You should be able to find out which one, and that it holds a state license. A brand name printed on a vial doesn't tell you who made what's inside it.

5. Nobody tells you approval is certain. Any site promising an outcome before a clinician has read a word of your history is describing a rubber stamp.

6. Refills involve a person. A subscription that keeps shipping while nobody checks how you're doing is a delivery service. Somewhere in the cycle, someone should be asking how it's going.

7. You can reach a clinician afterwards. The questions that matter tend to arrive weeks in rather than on day one — nausea that won't settle, a dose that feels wrong, a new prescription from another doctor. Find out now who answers those.

What the FDA told fifteen telehealth companies in June

As of September 6, 2026, the day this article was written, the most recent federal action aimed squarely at this corner of the market was a batch of warning letters the FDA issued on June 8, 2026 and posted publicly on June 16. At least fifteen telehealth companies selling compounded semaglutide and tirzepatide received one.

What the agency objected to falls into three groups, and each one is something you can check on a website in about a minute.

The first was marketing that made a compounded medicine sound as though the agency had reviewed it — language about proof of effectiveness that, in FDA's reading, describes an approved product and not a compounded one.

The second was how the pharmacy was described. Several sites described their supplier in a way FDA says is not accurate: calling it an "FDA approved" or "FDA-licensed" facility. The agency's answer in the letter to Maximus Health was blunt — compounding facilities, pharmacies and outsourcing facilities alike, are not "FDA-approved" or "FDA-licensed" entities. There is no such designation to hold.

The third was the label itself. On several sites the vial in the photograph carried the telehealth brand's own name, which made it look as though that company had compounded the medicine. FDA's letter to Eden Health asked the company to identify who actually produced the drugs.

None of that makes a compounded prescription a bad idea. FDA's position on compounded copies is a fact worth knowing, not a verdict on you: a licensed provider may still prescribe a compounded formulation, and that decision is between you and your doctor. What the letters give you is a free checklist written by the regulator.

Why the pharmacy behind the vial matters

Compounding means a licensed pharmacist prepares your medicine individually, rather than a factory turning out millions of identical pens. That's an ordinary, lawful part of American pharmacy. The variable is who is doing it.

A 2026 analysis in Expert Opinion on Drug Safety went through 81,078 GLP-1 reports in FDA's adverse-event database covering 2018 to 2024. Seven hundred and seven of them involved compounded products. Compared with the manufactured versions, those reports carried much higher reported odds of preparation errors and prescribing errors, and roughly double the odds that a hospitalization was mentioned (McCall et al., 2026). A reporting database can't prove cause and effect — people report what worries them, and the mix of who uses what differs. But preparation and prescribing are exactly the two steps a careful pharmacy and a careful prescriber control.

The everyday version of that risk is simpler. A nine-year review of GLP-1 calls to one regional poison center found 237 cases, and about seven in ten — 69.2% — were unintentional therapeutic errors, meaning someone took the wrong amount without meaning to (Muschler et al., 2025). Most were mild. A handful were not.

FDA's own consumer guidance, current as of September 1, 2026, lands in the same place: buy only from state-licensed pharmacies, and be wary of a telehealth service that doesn't require a licensed doctor's prescription, of prices that look too good, and of packaging that arrives damaged.

What a real intake asks you

The approved brands give you a benchmark for what a serious questionnaire covers. The Zepbound label, revised in August 2026, rules the medicine out entirely for anyone with a personal or family history of medullary thyroid carcinoma — a rare thyroid cancer — or with MEN 2, an inherited condition that raises the risk of it. It also rules it out after a serious allergic reaction to tirzepatide.

So an intake worth the name asks about thyroid cancer in your family. It asks about pancreatitis, gallbladder trouble, kidney disease, and any diabetes medicine you take, because insulin and some older tablets change the low-blood-sugar picture. It asks whether you're pregnant, breastfeeding or trying to be.

This is a medicine with real effects. In SURMOUNT-1, a 2022 trial of 2,539 adults published in the New England Journal of Medicine, average body weight fell about 21% over 72 weeks on the highest dose, against about 3% on placebo (Jastreboff et al., 2022). Something that moves the body that much earns a careful look at your history first.

If none of those questions came up, the review wasn't a review.

Where Promise sits

Plainly, and once. Every treatment here has its own intake, because the questions a provider needs before tirzepatide are not the questions they need before something else. A licensed provider reviews every request and prescribes only when it's appropriate for you — not everyone qualifies. If a prescription is written, a licensed U.S. compounding pharmacy fills it and ships it, and follow-up check-ins are part of the plan rather than an upsell. Prices sit on the product page before you start an intake; what tirzepatide costs compares the routes, and how to get tirzepatide prescribed walks through the visit itself.

Tirzepatide here is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Zepbound and Mounjaro are the approved brands, and we set out what that distinction actually means on a separate page about why compounded tirzepatide is not FDA-approved.

The whole checklist above takes about twenty minutes to run, and most people skip every step of it. Twenty minutes is cheap next to a year of injecting something you can't trace back to a pharmacy or a name.

Common questions

How do I know if a tirzepatide provider is legitimate?

Check four things. The prescribing clinician holds a license in the state where you will be during the visit. The intake asks about your medical history, medications and family history, not only your weight. The service names the pharmacy that compounds the medicine. And a clinician can decline you. A site that cannot give you all four is selling convenience rather than care.

Is compounded tirzepatide FDA-approved?

No. FDA-approved tirzepatide products exist — Zepbound and Mounjaro — but the compounded formulations prescribed through telehealth services are not FDA-approved. Compounding is a lawful part of pharmacy practice, and a licensed provider may still prescribe a compounded formulation where they judge it appropriate. That decision sits with you and your doctor.

Does my tirzepatide provider have to be licensed in my state?

Yes. Medical practice is generally treated as happening where the patient is located, so the clinician needs authority in the state where you physically are during the visit — not where the company is based. That is why a careful service asks your state early. You can confirm a named clinician on the state board's own public record.

Can a telehealth provider refuse to prescribe tirzepatide?

Yes, and it is a sign the review is real. Providers decline for specific reasons: a personal or family history of medullary thyroid carcinoma, MEN 2, pregnancy, a drug interaction, or a history the medicine does not fit. If you are declined, ask why. The answer is often narrow and addressable rather than a permanent no.

What did the FDA warning letters to telehealth companies say?

The FDA issued letters on June 8, 2026, posted June 16, to at least fifteen telehealth companies selling compounded semaglutide and tirzepatide. The objections grouped into three themes: marketing that implied the agency had cleared a compounded product, describing a compounding pharmacy as FDA-approved or FDA-licensed when no such status exists, and vial labels carrying the telehealth brand's name rather than identifying the actual compounder.

Is a very cheap tirzepatide provider a warning sign?

It can be. FDA's consumer guidance names suspiciously low prices alongside services that do not require a licensed doctor's prescription and packaging that arrives damaged. Price alone proves nothing — compounded medicines are often cheaper than brand list prices — but an unusually low figure is worth pairing with the licensure and pharmacy checks before you commit.